Pharma & Life Sciences · Quality & Compliance

Qualification &
Validation.

IQ/OQ/PQ equipment qualification, process validation (PPQ), cleaning validation, analytical method validation (AMV) and computerised system validation (CSV/GAMP 5) — delivered as an integrated lifecycle programme connecting compliance to operational reliability for regulated manufacturers across the UK, Europe, Africa and the Middle East.

Request a scoping call Method Development

5 Types

IQ/OQ/PQ, PPQ, cleaning validation, AMV and CSV/GAMP 5 — delivered within a single integrated programme or as standalone engagements

Lifecycle

FDA 3-stage approach: process design → process performance qualification (PPQ) → continued process verification (CPV) — managed as an ongoing asset

Audit-Ready

full GxP-compliant documentation packages — protocols, execution records and summary reports — aligned to FDA, MHRA and EMA inspection expectations

The Challenge

Validation as a
one-time event
is the problem.

Pharmaceutical manufacturers know that qualification and validation are legal requirements. What they often discover too late is that validation programmes built on the old paradigm — fixed batches, binary pass/fail, filed and forgotten — create a fragile compliance position that deteriorates with every equipment change, process modification and software upgrade.

The FDA's lifecycle approach to process validation, mandated since 2011 and reinforced by ICH Q8–Q12, requires that validation evidence is continuously generated and that the process remains in a state of control through Continued Process Verification (CPV). Yet the majority of regulated manufacturers still treat validation as Stage 2 only — executing PPQ batches, filing the report, and moving on. The absence of Stage 3 CPV programmes is one of the most common and consequential gaps identified in regulatory inspections.

Optimal delivers qualification and validation as an integrated operational programme — connecting the compliance requirement to the ongoing reliability of your manufacturing assets and processes. The output is a validation system that strengthens rather than constrains operational performance.

The Optimal Asset Management Lens

Qualification and validation are, at their core, asset and process reliability programmes with a regulatory reporting requirement. Optimal brings its deep expertise in asset reliability, RCM, maintenance strategy and process performance management to bear on every validation programme — identifying failure modes in equipment and processes that undermine validation state, aligning qualification protocols to maintenance strategy, and designing CPV programmes that function as operational performance monitoring systems. Compliance and reliability are not competing objectives. Designed correctly, they reinforce each other.

Scope of Service

Five validation types.
One integrated programme.

Optimal delivers the full spectrum of qualification and validation activities required in regulated pharmaceutical, biotech and chemical manufacturing environments.

IQ/OQ/PQ

Equipment Qualification

Installation Qualification (IQ), Operational Qualification (OQ) and Performance Qualification (PQ) for manufacturing equipment, laboratory instruments, utilities and facility systems. Risk-based qualification protocols proportionate to GxP criticality — from manufacturing equipment and HVAC to analytical balances and autoclaves. Includes User Requirement Specification (URS) review, Design Qualification (DQ) where applicable, and ongoing requalification programme management.

EU GMP Annex 15FDA 21 CFR 211Risk-basedURS / DQ

PPQ

Process Validation (PPQ)

Process Performance Qualification (PPQ) and Continued Process Verification (CPV) delivered under the FDA lifecycle approach. Includes process design review and CPP/CQA mapping, PPQ protocol development with statistically justified sampling plans, execution oversight and batch record review, PPQ summary report compilation, and design and implementation of Stage 3 CPV statistical monitoring programmes using SPC to demonstrate ongoing process control. Science- and risk-based approach per FDA PV Guidance (2011) and ICH Q8(R2)/Q10.

FDA LifecycleCPP / CQACPV / SPCICH Q8(R2)

Cleaning Validation

Cleaning validation programmes for multi-product pharmaceutical manufacturing equipment in compliance with EU GMP Annex 15 and FDA guidance. Includes Health-Based Exposure Limit (HBEL) and Acceptable Daily Exposure (ADE) assessments per EMA guideline, worst-case equipment and product identification, sampling strategy development (swab and rinse), analytical method qualification, and acceptance criteria establishment. Validation master plan and protocols through to summary report and lifecycle management plan.

EU GMP Annex 15HBEL / ADEEMA GuidelineMulti-product

AMV

Analytical Method Validation

Full analytical method validation per ICH Q2(R2) (effective June 2024), covering specificity/selectivity, accuracy, precision (repeatability, intermediate precision, reproducibility), linearity, range, detection limit, quantitation limit and robustness. Validation strategy aligned to method purpose and regulatory context — including compendial method verification, partial validation for method modifications, and co-validation for multi-site transfers. Integration with Optimal Method Development programmes to provide a seamless development-to-validated state pathway.

ICH Q2(R2) 2024SpecificityPrecision / AccuracyRobustness

CSV

Computerised System Validation

GAMP 5-aligned validation of computerised systems used in GxP-regulated operations: LIMS, chromatography data systems (CDS), MES, ERP, CMMS, QMS and process historians. Full IQ/OQ/PQ documentation per GAMP 5 Category 3–5. Data integrity assessments aligned to FDA guidance on data integrity and ALCOA+ principles. EU Annex 11 and FDA 21 CFR Part 11 (electronic records and signatures) compliance review. Periodic review and revalidation programme management.

GAMP 521 CFR Part 11EU Annex 11Data IntegrityALCOA+

Integrated

Validation Master Planning

For organisations establishing or restructuring their validation programme, Optimal develops Validation Master Plans (VMPs) that define the overall validation philosophy, scope, responsibilities, documentation requirements and validation state management approach across the site. VMPs are structured to meet EU GMP Annex 15 and FDA expectations and are designed to function as living operational governance documents — not as static compliance artefacts that immediately become out of date.

VMPEU GMP Annex 15Site-wideGovernance

FDA Lifecycle Approach

Process validation
that does not stop
at PPQ.

The FDA Process Validation Guidance (2011) establishes a three-stage lifecycle model. Most manufacturers execute Stage 2 and treat Stage 3 as optional. Optimal designs programmes that function across all three stages — because Stage 3 is where the commercial value of validation is realised.

Process Design

Capturing process knowledge & design intent

Development and scale-up activities that define the commercial manufacturing process. Optimal supports Stage 1 through process design review, CQA and CPP mapping using risk assessment (ICH Q9), design space definition under ICH Q8(R2), and development of the control strategy that will underpin PPQ and CPV. The quality of Stage 1 documentation directly determines the scientific rigour of PPQ justification and the defensibility of the control strategy under inspection.

Process Qualification

Demonstrating commercial process capability

Equipment qualification (IQ/OQ/PQ), facility and utility qualification, and Process Performance Qualification (PPQ). Optimal develops risk-based PPQ protocols with statistically justified sampling plans, provides execution oversight and deviation management, and compiles GxP-compliant PPQ summary reports meeting both FDA and EMA inspection expectations. PPQ is not a batch count decision — it is a scientific evidence decision, and Optimal's protocols reflect that.

Continued Process Verification

Maintaining the validated state through commercial manufacture

The ongoing programme that demonstrates the process remains in a state of control throughout commercial manufacture. Optimal designs and implements CPV programmes using statistical process control (SPC) — control charts, process capability indices (Cpk), multivariate statistical analysis — to provide ongoing assurance and to detect adverse trends before they become failures. CPV data directly feeds annual product reviews and supports post-approval change management under ICH Q12.

Documentation

Full GxP documentation
across every activity.

Optimal produces all validation documentation to GxP standards, formatted for regulatory submission and structured for practical operational use.

Document	Activity	Regulatory Alignment
Validation Master Plan (VMP)	All validation activities	EU GMP Annex 15; FDA PV Guidance 2011
User Requirements Specification (URS)	Equipment qualification; CSV	GAMP 5; EU GMP Annex 15
Functional & Design Specification	CSV Category 4–5 systems	GAMP 5 V-model; 21 CFR Part 11
IQ / OQ / PQ Protocols & Reports	Equipment qualification; CSV	EU GMP Annex 15; 21 CFR 211; GAMP 5
PPQ Protocol & Summary Report	Process validation	FDA PV Guidance 2011; ICH Q8(R2); EU GMP Annex 15
Cleaning Validation Protocol & Report	Cleaning validation	EU GMP Annex 15; EMA/CHMP/CVMP/SWP/463311/2016
Analytical Method Validation Protocol & Report	AMV	ICH Q2(R2) 2024; USP <1225>; Ph. Eur. 2.9.x
Risk Assessment (FMEA / HARA)	All activities	ICH Q9; GAMP 5; EU GMP Annex 15
Data Integrity Assessment	CSV	MHRA Data Integrity Guidance 2021; FDA 2018 Guidance; ALCOA+
CPV Statistical Monitoring Report	Process validation (Stage 3)	FDA PV Guidance 2011 Stage 3; ICH Q10; Annual Product Review

Regulatory Alignment

Qualified for the
regulators you face.

Every validation programme Optimal delivers is aligned to the regulatory frameworks applicable to your facility, product type and target markets.

FDA 21 CFR Part 211

US Current Good Manufacturing Practice for finished pharmaceuticals. Sections 211.68 (computerised systems), 211.100 (production and process controls) and 211.165 (testing and release) define the primary validation requirements enforced by FDA inspection. Process Validation: General Principles and Practices (2011) is the authoritative guidance document.

EU GMP Annex 15

EudraLex Volume 4 Annex 15 (Qualification and Validation) and Annex 11 (Computerised Systems) define European GMP requirements. Annex 15 was revised in 2015 to align with the lifecycle approach and requires risk-based qualification, cleaning validation per health-based limits and ongoing process verification.

GAMP 5 (Second Edition)

ISPE Good Automated Manufacturing Practice 5 (Second Edition, 2022) provides the risk-based framework for computerised system validation. Software categorisation (Categories 1, 3, 4, 5) determines the validation approach and documentation requirements. Optimal applies the updated GAMP 5 Second Edition risk-based thinking across all CSV programmes.

ICH Q2(R2) — 2024

Revised analytical method validation guideline effective June 2024, replacing Q2(R1). Expands scope to include multivariate and spectroscopic methods, introduces enhanced validation approaches aligned with ICH Q14 lifecycle framework, and provides updated guidance on partial validation, method transfers and system suitability.

MHRA & UK GMP

MHRA operates an independent GMP framework post-Brexit while maintaining substantial alignment with EU GMP. MHRA's 2021 Data Integrity Guidance is the definitive UK reference for data integrity in computerised systems validation. MHRA inspection focus on validation state maintenance and CPV programmes has intensified in recent years.

ICH Q8(R2), Q9 & Q10

Pharmaceutical Development, Quality Risk Management and Pharmaceutical Quality System guidelines that provide the conceptual framework for modern validation programmes. Design space, FMEA-based risk assessment, change control and continued process verification are all grounded in this ICH Quality trilogy.

Related Services

Services that work alongside
qualification & validation.

Method Development

Science- and risk-based method development across analytical, cleaning, microbiological and manufacturing process disciplines. Methods developed within Optimal's ICH Q14 lifecycle framework arrive at validation with ATP-defined acceptance criteria and MODR-informed robustness data, significantly reducing AMV execution time and regulatory risk.

Learn more

Asset Maintenance Strategy

Equipment failures are among the leading causes of process validation excursions and CAPA-triggering quality events. A structured RCM-based maintenance strategy reduces the equipment-driven variability that undermines process control and threatens validated state. Optimal integrates qualification and maintenance strategy from the outset.

Learn more

QMS Gap Assessment

ISO 9001 and GxP QMS gap assessments that identify weaknesses in validation governance, change control, CAPA management and document control systems. QMS gaps in validation-related procedures are one of the most frequent sources of repeat regulatory findings. Optimal's gap assessment and remediation programme addresses root causes, not just observations.

Learn more

Qualification &Validation.

Validation as aone-time eventis the problem.

Five validation types.One integrated programme.

Process validationthat does not stopat PPQ.

Full GxP documentationacross every activity.

Qualified for theregulators you face.

Services that work alongsidequalification & validation.

Ready to build a validation programme that holds?

Qualification &
Validation.

Validation as a
one-time event
is the problem.

Five validation types.
One integrated programme.

Process validation
that does not stop
at PPQ.

Full GxP documentation
across every activity.

Qualified for the
regulators you face.

Services that work alongside
qualification & validation.